AUTO-IMMUNE AND INFLAMMATORY DISEASES IN CHILDREN WITH SICKLE CELL DISEASE: DIAGNOSTIC AND THERAPEUTIC ISSUES

Caroline Vint1, Corinne Guillon2, Patricia Benhaim1, Florence Missaud2, Mariane De Montalembert1, Lahoueri Amor1, Cécile Arnaud2, Oussama Charara3, Vincent Gadgos1, Véronique Hentgen4, Annie Kamdem5, Sylvie Nathanson6, Brigitte Bader-Meunier1, Isabelle Melki1, Isabelle Koné-Paut4, Pierre Quartier1, Loïc De Pontual5, Luu-Ly Pham6, J.Verdier hospital, Bondy, France;1 Bicêtre hospital, Kremlin Bicêtre, France;2 Dédragé hospital, Paris, France;3 Neckfer hospital, Paris, France;4 CHIC, Creil, France;5 A.Mignot Hospital, Versailles, France;6 A.Bécéole hospital, Clamart, France

Background: Coexistent auto-immune and inflammatory diseases (AID) and sickle cell disease (SCD) have been recently described in adults affected, however their frequency and pathophysiology remain unclear (1–6).

Objectives: The aim of this study is the analysis of clinical and biological characteristics at AID diagnosis and the evolution under treatment in children with SCD

Methods: Between May 1991 and March 2018, 35 of 3,800 SCD children diagnosed with AID in seven hospitals in Paris and suburb were analysed in a retrospective survey.

Results: Thirty-five patients reported 44 AID: auto-immune liver disease (AILD, n=13), inflammatory bowel disease (IBD, n=7), juvenile idiopathic arthritis (JIA, n=6), systemic lupus erythematosus (n=5), autoimmune hemolytic anemia (n=3), Sjögren’s syndrome (n=2), histiocytic necrotizing lymphadenitis (n=2), vasculitis (n=2), myasthenia gravis (n=2), sarcoidosis (n=2), inflammatory uveitis (n=1), scleroderma/juvenile dermatomyositis (n=1). Median age at diagnosis was 10 [2–18] years. The mean delay between first symptom and diagnosis was 15.5 (± 29) months. The time of diagnostic was significantly longer for patients with JIA compared to other AID (63 versus 10 days, p=0.004). Sixteen patients (45.7%) had hypergammaglobulinemia > 20 g/L at diagnosis. AILD had a hypergammaglobulinemia at the time of diagnosis (30.0g/L), with a statically significant decrease at the end of follow-up (18.2g/L, p=0.0048). Among 21 patients (60%) treated with systemic steroids, it triggered vaso-occlusive crisis in 14 (66.7%), one acute chest syndrome, one transient ischemic attack. Thirteen of 35 patients (37.1%) were managed with biotherapy for AILD, well tolerated. Three patients (8.6%) underwent stem cell transplantation, one died of a cortico-resistant and multipolar graft versus host reaction, two were cured of both AILD and SCD. Nine severe infections were reported, four under steroids, five under biotherapy.

Conclusion: Diagnosis and therapeutic care of coexistent auto-immune and inflammatory diseases are difficult and challenging in children with SCD. Annual monitoring of inflammatory markers could be recommended to detect AILD earlier and prevent diagnostic delay in case of high ascension in SCD patients.

REFERENCES

Disclosure of Interests: Caroline Vint: None declared, Corinne Guillon: None declared, Patricia Benhaim: None declared, Florence Missaud: None declared, Mariane De Montalembert: None declared, Lahoueri Amor: None declared, Cécile Arnaud: None declared, Oussama Charara: None declared, Vincent Gadgos: None declared, Véronique Hentgen Consultant for: SOBI, Novartis, Abbvie, Speakers bureau: Novartis, Anne Kamdem: None declared, Sylvie Nathanson: None declared, Brigitte Bader-Meunier: None declared, Isabelle Melki: None declared, Isabelle Koné-Paut Grant/ research support from: SOBI has supported drug product (anakinra) for the presented study, Consultant for: SOBI, Novartis, Pfizer, Abbvie, UCB, CHUGAI, ROCHE, Pierre Quartier Consultant for: Abbvie, Chugai-Roche, Lilly, Novartis, Novimmune, Sanofi, and SOBI, Consultant for: Abbvie, Chugai-Roche, Lilly, Novartis, Novimmune, Sanofi, and SOBI, Speakers bureau: AbbVie, BMS, Chugai-Roche, Novartis, Pfizer, and SOBI, Speakers bureau: AbbVie, BMS, Chugai-Roche, Novartis, Pfizer, and SOBI, Luu-Ly Pham: None declared


AB1072 UVEITIS IN PEDIATRIC RHEUMATOLOGY: TERTIARY CENTER EXPERIENCE IN TURKEY

Zahide Ekiç Tekin1, Gulcin Otar Yener2, Ebru Nevin Çetin3, Seilen Akbultu4, Selen Ubaydulkasim5, Selcuk Yuksel6, Pamukkale University Faculty of Medicine, Pediatric Rheumatology, Denizli, Turkey; 7Pamukkale University Faculty of Medicine, Ophthalmology, Denizli, Turkey

Background: Since pediatric uveitis is generally asymptomatic, the diagnosis and treatment may be mostly delayed. Severe complications and visual loss may be observed even at the initial visit. Pediatric uveitis is tend to be chronic, persistent, recurrent, and the management may be complex (1).

Objectives: The aim of this study is to report epidemiology, etiology, clinical features, management and the outcomes of non infectious pediatric uveitis at a tertiary pediatric rheumatology center in Turkey.

Methods: The clinical records of the patients with non infectious uveitis who were followed up by department of pediatric rheumatology and ophthalmology were reviewed, from January 2013 to June 2018, retrospectively. The inclusion criteria were as follows being age ≤ 16 years, following up at least 6 months in both the ophthalmology and pediatric rheumatology clinics. Uveitis was categorized anatomically according to the Standardization of Uveitis Nomenclature criteria (2).

Results: Of 37 patients (67 eyes), 45.9% were female. Mean age of onset was 8, 5 ± 4, 4 years (1.6 - 15.6), mean follow-up was 60 ± 42 months (6 - 191). The general features of uveitis were anterior, idiopathic and bilateral in this study similar to literature (Table 1).The most common systemic diseases associated with uveitis were juvenile idiopathic arthritis (JIA); Two patients improved with local medications, while the remaining 35 patients required systemic treatments such as short-time (oral/ iv) corticosteroids (CS) in 94.5% of them, methotrexate (MTX) in 86.4%, azathioprine (AZA) in 5.4%, adalimumab (ADA) in 67.5%, tocilizumab (TCB) in 2.7%. In 26.1% of patients receiving ADA who did not respond to standard dose of ADA, we had to shorten the dosage intervals of ADA from every 2 weeks to every week. At least 1 ocular complication was observed in 83.7% of the patients, such as cataract, glaucoma, band keratopathy, synchiae, macular edema and retinal detachment. Four (10.8%) patients had moderate visual loss and 6 (16.2%) patients severe visual loss (3). The prevalence of surgery in our study was 18.9% for cataract and glaucoma treatment.

Conclusion: Diagnosis and management of uveitis in childhood is complicated. Despite the new medication options, the advancements in diagnosis in patients with unresponsive to standard dosage of ADA. However